161 related articles for article (PubMed ID: 22941375)
1. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
Infante JR; Keedy VL; Jones SF; Zamboni WC; Chan E; Bendell JC; Lee W; Wu H; Ikeda S; Kodaira H; Rothenberg ML; Burris HA
Cancer Chemother Pharmacol; 2012 Nov; 70(5):699-705. PubMed ID: 22941375
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
Burris HA; Infante JR; Anthony Greco F; Thompson DS; Barton JH; Bendell JC; Nambu Y; Watanabe N; Jones SF
Cancer Chemother Pharmacol; 2016 May; 77(5):1079-86. PubMed ID: 27061418
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
Chang TC; Shiah HS; Yang CH; Yeh KH; Cheng AL; Shen BN; Wang YW; Yeh CG; Chiang NJ; Chang JY; Chen LT
Cancer Chemother Pharmacol; 2015 Mar; 75(3):579-86. PubMed ID: 25577133
[TBL] [Abstract][Full Text] [Related]
5. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y
Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
Innocenti F; Schilsky RL; RamÃrez J; Janisch L; Undevia S; House LK; Das S; Wu K; Turcich M; Marsh R; Karrison T; Maitland ML; Salgia R; Ratain MJ
J Clin Oncol; 2014 Aug; 32(22):2328-34. PubMed ID: 24958824
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Clarke JL; Molinaro AM; Cabrera JR; DeSilva AA; Rabbitt JE; Prey J; Drummond DC; Kim J; Noble C; Fitzgerald JB; Chang SM; Butowski NA; Taylor JW; Park JW; Prados MD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):603-610. PubMed ID: 28233053
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Herben VM; Schellens JH; Swart M; Gruia G; Vernillet L; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
Wu H; Infante JR; Keedy VL; Jones SF; Chan E; Bendell JC; Lee W; Kirschbrown WP; Zamboni BA; Ikeda S; Kodaira H; Rothenberg ML; Burris HA; Zamboni WC
Int J Nanomedicine; 2015; 10():1201-9. PubMed ID: 25709442
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
Rowinsky EK; Rizzo J; Ochoa L; Takimoto CH; Forouzesh B; Schwartz G; Hammond LA; Patnaik A; Kwiatek J; Goetz A; Denis L; McGuire J; Tolcher AW
J Clin Oncol; 2003 Jan; 21(1):148-57. PubMed ID: 12506184
[TBL] [Abstract][Full Text] [Related]
12. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K
Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280
[TBL] [Abstract][Full Text] [Related]
14. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.
Wu H; Infante JR; Keedy VL; Jones SF; Chan E; Bendell JC; Lee W; Zamboni BA; Ikeda S; Kodaira H; Rothenberg ML; Burris HA; Zamboni WC
Eur J Clin Pharmacol; 2013 Dec; 69(12):2073-81. PubMed ID: 23989300
[TBL] [Abstract][Full Text] [Related]
16. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.
Chiang NJ; Chao TY; Hsieh RK; Wang CH; Wang YW; Yeh CG; Chen LT
BMC Cancer; 2016 Nov; 16(1):907. PubMed ID: 27871319
[TBL] [Abstract][Full Text] [Related]
17. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
[TBL] [Abstract][Full Text] [Related]
19. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
